VANCOUVER, BC / ACCESSWIRE / April 3, 2023 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTCQB:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its second quarter financial results (“Q2 2023”) For the six months ended January 31, 2023, and 2022. All amounts expressed are in Canadian dollars.
The Company owns 91% of Alternative Medicine Association (AMA), the Company’s cultivation and production subsidiary focused on the medical and adult-use cannabis market, and 100% of CBD product manufacturer Infused MFG LLC (Infused). The Company’s revenue is derived from wholesale cannabis sales in Nevada (AMA), and from the sale of hemp-derived consumer packaged goods (Infused) under the Canna Hemp™ brand sold across the US via e-commerce at cannahemp.com.
Q1 2023 Financial Highlights
- Revenue $3.6 million for Q2 2023 and $9.2 million for the six months ended January 31, 2023
- Expenses $0.2 million
- Gross margin $1.9 million before adjustments
- Net loss $0.4 million
- Adjusted EBITDA $0.1 million – Second consecutive quarter of positive EBITDA
Consolidated Operating Highlights
- Total revenues were $3.6 million for Q2 2023, representing a 13% increase over $3.2 million for Q2 2022. Revenues are $9.2 million for the six months ended January 31, 2023, representing a 52% increase from $6.0 million during the same period in 2022.
- Expenses of $0.2 million for Q2 2023 decreased by 92% from $2.4 million in Q2 2022 in large part due to a substantial tax refund from the IRS. The Company continues to work diligently on controlling expenses.
- Gross margin was $1.9 million, before fair value adjustments on biological assets and realized fair value adjustments on the sale of inventory. The decrease in gross margin is attributable to a decrease in flower pricing in Nevada.
- Net loss was $0.4 million for Q2 2023 and $0.8 million for Q2 2022.
- Adjusted EBITDA was $0.1 million for Q2 2023 and $0.1 million for Q2 2022.
- Cash at the end of the period was $2.9 million compared to $0.8 million during the same period in 2022.
Mr. Paul Rosen, Chairman and CEO of 1933 Industries commented, “Wholesale pricing pressure continues to impact cultivators in Nevada, with lower sale prices on cannabis products experienced across the industry. In addition, the Company has chosen to deal with some legacy infrastructure issues that compressed our overall capacity this quarter. During the reporting period, the Company continued to focus on strengthening its operation. Necessary and essential infrastructure improvements to the Company’s cultivation facility, including improvements to the facility’s irrigation, air movement and humidification systems have been initialized and are well underway. A build-up of inventory will be the Company’s priorities in the following quarters in order to increase the production of sellable dried flower and pre-rolls. We expect flower prices to stabilize in the near future, and we expect as well that the launch of consumption lounges will create a new attraction for visitors to the state and expand cannabis-related tourism. The Company is well positioned to benefit from increased demand, flower price stabilization, and the strength of its top brand and in-demand products that deliver excellent value to consumers.
Operationally, the Company has made substantial improvements in lowering its debt load, reducing expenses, and conserving its working capital over the last several quarters. The Company recorded positive Adjusted EBITDA for a second quarter in a row, a milestone in the Company’s history.”
Appointment of Ester Vigil as President
The Company is pleased to announce that Ms. Ester Vigil has been appointed as President. Ms. Vigil previously held the role of Director of Sales and served as president from 2019 to 2020. Ms. Vigil’s return to the Company has been marked by significant achievements, including repositioning AMA as a top brand in Nevada. “Ester’s contributions to the Company are very meaningful,” said Mr. Rosen. “She has added value in all areas of our business, and her leadership has earned her esteem and respect from both her colleagues at 1933, and throughout the overall Nevada cannabis industry. I look forward to Ester continuing to help improve our business, deliver excellent value to our customers and deliver future growth.”
Financial statements are prepared in accordance with International Financial Reporting Standards. Detailed information regarding the Company’s financial results as well as management’s discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-information
Please note the next financial release dates in accordance with the continuous disclosure schedule set out by the British Columbia Securities Commission:
|2023 Financial Release Dates
|June 29, 2023
|November 28, 2023
|January 1, 2024
|April 2, 2024
|July 2, 2024
|November 28, 2024
About 1933 Industries Inc.
1933 Industries is a Nevada-based, growth-orientated company, focusing on the cultivation and manufacturing of a large portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. Its product offerings include: THC flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; Canna Hemp™, national cannabidiol (CBD) brand of infused wellness products including tinctures, gummies, topicals and sport recovery products. The Company owns 91% of Alternative Medicine Association, LC (AMA) and 100% of Infused MFG LLC (Infused).
About Alternative Medicine Association
AMA is a licensed medical and adult-use cannabis cultivation and extraction subsidiary that produces its own branded line of unique cannabis products. AMA’s extensive menu of cannabis products include: craft cannabis flower, pre-rolls, full spectrum oils, high quality distillates, proprietary blends of terpenes, vaporizer products and boutique concentrates such as shatter, crumble, batter, sugar wax, diamonds, and live resin. Ultra-craft brand Level X is an exclusive collection of exotic strains, selected specifically for their distinctive terpene profiles, high THC levels, and flavonoids. With state-of-the-art cultivation and extraction facilities based in Las Vegas, Nevada, AMA seeks to offer medical patients and recreational users alike a cannabis experience that’s exceptional, potent, and consistent in quality. www.amanev.com
AMA is also licensed in Nevada as an adult-use cannabis distributor.
About Canna Hemp™
With over 60 products in its portfolio, the Canna Hemp™ brand offers products in a variety of verticals and consumption formats, including, effects-based tinctures, topicals, vape pens and cartridges, gummies, and capsules for Sleep, Relief, Calm, Focus and Energy. High-grade CBD and a proprietary blend of terpenes formulated for specific effects are key differentiators for the Canna Hemp™ line. The Company recently introduced previously untapped cannabinoids Cannabigerol (CBG) and Cannabinol (CBN) to its portfolio of products with a new line of natural tinctures and gummies.
For further information please contact:
Alexia Helgason, VP, IR, Marketing, Media
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE: 1933 Industries Inc.
Company Relationship Disclosure
T420 is responsible for the T420 opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and T420 does not undertake to confirm or substantiate or be responsible for such information provided by other parties.
Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.
This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws